Who are Placebo First, then ORADUR®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SAMIDORPHAN L-MALATE, BENZHYDROCODONE, NALBUPHINE HYDROCHLORIDE, Methadone Hydrochloride, morphine ,ketorolac, Naloxone Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-first-then-oradur.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo First, then ORADUR® — Competitive Intelligence Brief

Placebo First, then ORADUR® (Placebo First, then ORADUR®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid partial agonist. Area: Pain management.

phase 3 Opioid partial agonist Opioid receptors Pain management Small molecule Live · refreshed every 30 min

Target snapshot

Placebo First, then ORADUR® (Placebo First, then ORADUR®) — Orient Pharma Co., Ltd.. ORADUR is a sustained-release formulation of buprenorphine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo First, then ORADUR® TARGET	Placebo First, then ORADUR®	Orient Pharma Co., Ltd.	phase 3	Opioid partial agonist	Opioid receptors
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
morphine ,ketorolac	morphine ,ketorolac	Jose Antonio Bernia Gil	marketed	Opioid analgesic + NSAID combination	Opioid receptors (μ, δ, κ); COX-1 and COX-2 enzymes
Naloxone Hydrochloride	Naloxone Hydrochloride	Pfizer Inc.	marketed	Mixed opioid agonist-antagonist with opioid antagonist	Opioid receptors (mu, kappa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-01 — Naloxone Hydrochloride · 7731686 · Formulation · US
2026-06-25 — Naloxone Hydrochloride · 10960155 · Formulation · US
2026-12-12 — Naloxone Hydrochloride · 11590286 · Formulation · US
2027-02-20 — Naloxone Hydrochloride · 9238108 · Formulation · US
2027-02-27 — Naloxone Hydrochloride · 8206360 · Formulation · US
2027-05-23 — Naloxone Hydrochloride · 9724471 · Formulation · US
2028-03-12 — Naloxone Hydrochloride · 7947017 · Formulation · US
2028-10-30 — Naloxone Hydrochloride · 7749194 · Formulation · US
2028-11-25 — Naloxone Hydrochloride · 8231573 · Formulation · US
2029-04-10 — Naloxone Hydrochloride · 8226610 · Formulation · US
2029-11-02 — Naloxone Hydrochloride · 8021344 · Formulation · US
2031-02-28 — Naloxone Hydrochloride · 9814838 · Formulation · US
2031-02-28 — Naloxone Hydrochloride · 8939943 · Formulation · US
2031-02-28 — Naloxone Hydrochloride · 9022022 · Formulation · US
2031-02-28 — Naloxone Hydrochloride · 10322239 · Method of Use · US
2031-02-28 — Naloxone Hydrochloride · 9474869 · Formulation · US
2031-05-24 — Naloxone Hydrochloride · 10143792 · Method of Use · US
2031-05-24 — Naloxone Hydrochloride · 10143972 · Method of Use · US
2032-02-04 — Naloxone Hydrochloride · 8627816 · Formulation · US
2032-05-11 — Naloxone Hydrochloride · 12458591 · Method of Use · US
2032-05-11 — Naloxone Hydrochloride · 11806428 · Formulation · US
2032-05-11 — Naloxone Hydrochloride · 11020343 · Method of Use · US
2034-07-18 — Naloxone Hydrochloride · 9517307 · Formulation · US
2034-08-26 — Naloxone Hydrochloride · 11135155 · Formulation · US
2034-08-26 — Naloxone Hydrochloride · 11617713 · Formulation · US
2034-08-26 — Naloxone Hydrochloride · 11628139 · Formulation · US
2034-08-26 — Naloxone Hydrochloride · 10973814 · Formulation · US
2034-08-26 — Naloxone Hydrochloride · 10722510 · Formulation · US
2034-08-26 — Naloxone Hydrochloride · 11975096 · Formulation · US
2034-08-26 — Naloxone Hydrochloride · 12414915 · Formulation · US

Sponsor landscape (Opioid partial agonist class)

Brigham and Women's Hospital · 1 drug in this class
Orexo AB · 1 drug in this class
Orient Pharma Co., Ltd. · 1 drug in this class
Rutgers, The State University of New Jersey · 1 drug in this class
Yih-Ing Hser · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo First, then ORADUR® — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-first-then-oradur. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab